Zenagamtide

Unimolecular GLP-1, amylin and calcitonin receptor agonist peptide

Obesitytype 2 diabetes

Zenagamtide

Evidence levelHuman Phase II

Human evidencePhase II

Regulatory statusInvestigational / not authorised

What you need to know in 20 seconds

What is it?	Unimolecular GLP-1, amylin and calcitonin receptor agonist peptide
Research focus	Obesity, type 2 diabetes, sleep apnoea, knee osteoarthritis, heart failure
Human evidence	Two peer-reviewed 2026 Phase II trials show significant HbA1c reductions with once-weekly subcutaneous and once-daily oral zenagamtide in type 2 diabetes.
Regulatory status	Investigational; Phase 3 obesity programme initiated in 2026. No general marketing authorisation identified.
Main limitations	Marketing approval, long-term cardiovascular outcomes, rare-event safety or final therapeutic dosing.
Safety	GI tolerability is the main recurring signal; early-phase attrition and formulation differences must be visible.

Two peer-reviewed 2026 Phase II trials show significant HbA1c reductions with once-weekly subcutaneous and once-daily oral zenagamtide in type 2 diabetes.

What the evidence actually supports

✓High-interest candidate with immature evidence; display phase prominently.
✓Strong Developing-to-Deep upgrade, while remaining investigational.
✓Keep formulation-specific evidence separate on one canonical molecule page.

What is not established / key limitations

×High withdrawal/attrition and small study parts reduce certainty; no approved dosing or long-term outcomes.
×No approval or long-term cardiovascular outcome evidence yet.
×Oral and subcutaneous formulations are not interchangeable and neither is approved.

Selected study & evidence records

Subcutaneous amycretin/zenagamtide Phase 1b/2a obesity study

2025 · Randomized controlled early-phase study · n=125

Estimated mean body-weight change included -24.3% at 60 mg vs -1.1% placebo at week 36; lower-dose groups also showed substantial loss.

Study detail → Primary source ↗

Once-weekly subcutaneous zenagamtide in type 2 diabetes

2026 · Randomized, double-blind, placebo-controlled dose-finding trial · n=262

HbA1c change ranged from -0.9% at 0.4 mg to -1.7% at 40 mg; all active groups showed significant improvement versus placebo.

Study detail → Primary source ↗

Once-daily oral zenagamtide in type 2 diabetes

2026 · Randomized, double-blind, placebo-controlled dose-finding trial · n=186

HbA1c fell by about 0.9%, 1.3% and 1.4% across the three active dose groups, significantly more than placebo.

Study detail → Primary source ↗

Safety and unknowns

GI tolerability is the main recurring signal; early-phase attrition and formulation differences must be visible.

Gastrointestinal events are frequent and mostly mild-to-moderate in early trials; early studies also had substantial participant withdrawal, requiring cautious interpretation.

Technical details

Mechanism / biologySingle peptide designed to combine GLP-1 receptor agonism with amylin/calcitonin-receptor-family activity affecting appetite, satiety and glucose regulation.

Route / formulation boundaryOral and subcutaneous regimens are formulation-specific and not interchangeable.

Identity / data-quality noteUse current name Zenagamtide and retain Amycretin as an alias for search continuity.

Dosing evidence statusEarly human dose-ranging verified; Phase 3 ongoing. Subcutaneous early-phase studies ranged from low single-mg doses to 60 mg weekly; later Phase 2 T2D studied 0.4–40 mg weekly. See study-specific records.

Identifiers & alternate namesAmycretin · former name amycretin